The abstract is read at the publisher; the summary is JClub's.
CUL5 knockout in primary human engineered T cells enhances tumor serial killing under repetitive antigen stimulation, sustaining cytotoxicity with fewer exhaustion marker-positive cells.
- Why it matters: Chronic tumor antigen exposure drives progressive T-cell dysfunction, limiting engineered therapies; negative-regulator disruption could sustain effector function during repeated stimulation.
- What they did: A reanalysis of a genome-wide CRISPR knockout screen plus protein-protein interaction mapping identified an enriched CRL5 complex cluster; CUL5 ablation was tested across multiple CAR/TCR designs and stimulation schedules, with ubiquitylation proteomics to define CRL5-dependent substrates.
- The result: CUL5 loss improved persistence and function across CARs targeting CD19, BCMA, and HER2 and in 1XX-modified CAR and HLA-independent TCR architectures, and in mice it increased bone marrow enrichment after repeated rechallenge with enhanced ex vivo cytotoxicity after nearly 90 days.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.